[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"side-effects\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:side-effects":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100616105","trial-of-the-mittin-intervention-to-improve-contraceptive-side-effect-counseling-and-follow-up-in-ethiopia-100616105",false,"NCT07301281","Trial of the \"Mittin\" Intervention to Improve Contraceptive Side Effect Counseling and Follow-up in Ethiopia","Cluster Randomized Controlled Trial of the \"Mittin\" Intervention in Addis Ababa, Ethiopia","Inclusion Criteria:\n\n* Woman\n* Started or continued using hormonal contraceptive method or copper IUD on day of recruitment\n* Ages 15-49 years\n* Willing to provide phone number and receive follow-up phone call\n\nExclusion Criteria:\n\n* Not planning to live in Addis Ababa for the next eight months\n* Can not verbally communicate\n* Not willing to provide consent for the study","FEMALE","15 Years","49 Years",{"count":20,"type":21},2715,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if the \"Mittin\" intervention can improve women's ability to manage their fertility in line with their preferences among women aged 15-49 using hormonal contraceptives or intrauterine devices and attending public health centers in Addis Ababa, Ethiopia. The main question it aims to answer is: Does the Mittin intervention increase preference-aligned fertility management, contraceptive method satisfaction, and preferred contraceptive method use among participants compared to standard care?\n\nResearchers will compare women's outcomes in health centers providing the Mittin intervention to women's outcomes in health centers that offer standard care to see if Mittin improves women's ability to act in line with their contraceptive preferences.\n\nParticipants will\n\n* Receive either standard contraception services (control arm) or enhanced services (intervention arm)\n* Participate in a survey at the beginning of the study\n* Participate in surveys 4 and 8 months later",[27,28],"Contraception","Side Effects","NOT_YET_RECRUITING","2025-12-10",{"date":32,"type":33},"2025-12-24","ACTUAL",{"date":35,"type":21},"2026-02",{"date":37,"type":21},"2027-06",{"name":39,"class":40},"University of California, San Francisco","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":41},"100601877","clinical-research-on-moderately-hypofractionated-adaptive-postoperative-radiotherapy-for-high-risk-endometrial-cancer-100601877","NCT07116213","Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer","Inclusion Criteria:\n\n* Age : 18-70 years old.\n* Performance Status :\n\nECOG score 0-2.\n\n* Expected to comply with oART (Online Adaptive Radiotherapy) workflow.\n* Initial Surgical Treatment :\n\nTotal hysterectomy and bilateral salpingo-oophorectomy ± Pelvic and\u002For para-aortic lymph node dissection\u002Fsampling or sentinel lymph node biopsy.\n\n* Pathological Staging \\& Histology (per FIGO 2009):\n\nStage I :\n\nGrade 3 endometrioid adenocarcinoma with superficial myometrial invasion and extensive LVSI (Lymphovascular Space Invasion).\n\nGrade 2 endometrioid adenocarcinoma with deep myometrial invasion and extensive LVSI.\n\nGrade 3 endometrioid adenocarcinoma with deep myometrial invasion. Stage II-IIIC1 : Endometrioid carcinoma. Stage I-IIIC1 : Serous carcinoma or clear cell carcinoma.\n\n* Informed Consent :\n* Patients and families fully understand the study protocol.\n* Voluntarily participate and sign informed consent forms before enrollment\n\nExclusion Criteria:\n\n* Prior Radiotherapy : History of abdominal or pelvic irradiation.\n* Treatment Interval :\n\nWithout adjuvant chemotherapy: \\>12 weeks between surgery and radiotherapy initiation.\n\nWith adjuvant chemotherapy: \\>6 months between surgery and radiotherapy initiation.\n\n* Malignancy History : Prior diagnosis of other malignancies.\n* Pregnancy\u002FLactation : Pregnant or breastfeeding women.\n* Active Infection : Fever or uncontrolled active infection.\n* Inflammatory Bowel Disease (IBD) : History of IBD (regardless of activity status).\n* Comorbidities : Severe conditions affecting trial compliance, including: Unstable cardiac disease requiring treatment, renal impairment, chronic hepatitis, poorly controlled diabetes, psychiatric disorders","18 Years","70 Years",{"count":51,"type":21},20,[24],"1. Study Type: Single-center, single-arm, prospective study.\n2. Sample Size: 20 patients with high-risk endometrial cancer were enrolled.\n3. Treatment Procedure:\n\n   The existing clinical oART (Online Adaptive Radiotherapy) workflow protocol for malignant tumors used in our department was applied.\n\n   Procedures included simulation, target volume delineation, radiotherapy planning, and treatment delivery.\n\n   External beam radiation therapy (EBRT) was delivered using moderate hypofractionation.\n\n   If indicated, brachytherapy was performed after the completion of EBRT. When combined with chemotherapy, radiotherapy could be administered during chemotherapy intervals or after completion of chemotherapy.\n4. Study Endpoints:\n\nPrimary Endpoint: Incidence of acute toxicity. Secondary Endpoints: 3-year failure-free survival (FFS) rate, incidence of chronic toxicity, quality of life (QoL), treatment costs, etc.",[55,56,57,28,58],"Endometrial Cancer","Hypofractionated Dose","Radiotherapy, Adjuvant","Survival , Tumor",[60,61,62],"endometrial cancer","Hypofractionated dose","Radiotherapy","RECRUITING","2025-08-04",{"date":66,"type":33},"2025-08-11",{"date":68,"type":33},"2025-06-30",{"date":70,"type":21},"2030-12-30",{"name":72,"class":40},"Xiaorong Hou",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":93,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100589537","effect-of-cryotherapy-in-the-prevention-of-madarosis-produced-by-chemotherapy-in-breast-cancer-patients-100589537","NCT06955702","Effect of Cryotherapy in the Prevention of Madarosis Produced by Chemotherapy in Breast Cancer Patients","Effect of Cryotherapy in the Prevention of Alopecia in Eyebrows and Eyelashes in Breast Cancer Patients Treated With Anthracyclines and Taxanes","Inclusion Criteria:\n\n* Female participants aged ≥18 years\n* Newly diagnosed breast cancer (any stage)\n* Scheduled to receive anthracycline- and\u002For taxane-based chemotherapy as first-line systemic treatment\n* No prior history of antineoplastic treatment\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Patients with recurrent disease who have received prior hormone therapy, chemotherapy, and\u002For immunotherapy\n* Presence of alopecia prior to the initiation of cancer treatment\n* History of cerebral radiotherapy",true,{"count":82,"type":21},120,[24],"Chemotherapy-induced alopecia (CIA) significantly compromises body image in breast cancer patients, particularly when involving eyebrow and eyelash loss (madarosis). While scalp cooling devices are routinely employed to prevent scalp alopecia, no standardized interventions exist for madarosis prevention. This quasi-experimental study assesses the efficacy of targeted eyebrow cryotherapy in reducing anthracycline- and taxane-induced madarosis.\n\nThe trial will enroll patients from two tertiary hospitals in Salamanca (intervention arm: cryotherapy) and a control cohort from Santander. Cryotherapy will be administered (-4°C to -7°C) 15 minutes pre-chemotherapy infusion and maintained for 20 minutes post-infusion. Primary outcomes include hair retention quantified through photogrammetric analysis (TIDOP Research Group) at four timepoints: baseline, mid-treatment, chemotherapy completion, and 1-month follow-up. Secondary endpoints evaluate quality of life (QLQ-C30 validated scales) and cryotherapy-related adverse events (CTCAE v5.0 criteria).\n\nThis investigation aims to establish the first evidence-based protocol for madarosis prevention and develop a novel alopecia classification scale, addressing a critical gap in supportive oncology care",[86,87,88,89,90,91,92,28],"Breast Neoplasms","Alopecia","Madarosis","Eyebrow Diseases","Eyelash Diseases","Anthracyclines","Taxoids",[94,88,95,96,97,98,99,100,101,102],"Chemotherapy-induced alopecia","Eyebrow preservation","Taxane-induced alopecia","Anthracycline-induced alopecia","Cryotherapy","Supportive care in oncology","Quality of life","Scalp cooling","Patient-reported outcomes","2025-05-17",{"date":105,"type":33},"2025-05-22",{"date":107,"type":33},"2023-11-15",{"date":109,"type":21},"2026-08-31",{"name":111,"class":40},"University of Salamanca",2]